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High MET Gene Copy Number Leads to Shorter Survival in
Patients with Non-small Cell Lung Cancer
Heounjeong Go, MD,*† Yoon Kyung Jeon, MD, PhD,*† Hyo Jin Park, MD,‡
Sook-Whan Sung, MD, PhD,§ Jeong-Wook Seo, MD, PhD,* and Doo Hyun Chung, MD, PhD*
Introduction: Activation of MET, either by increased gene copy
number (GCN) or mutation, has been detected in various cancers.
We investigate the clinicopathologic features of MET gene copy in
nonsmall cell lung cancer (NSCLC).
Methods: Tumor tissues were obtained from 180 resected NSCLCs,
including 97 squamous cell carcinomas (SCCs) and 72 adenocarci-
nomas. No patient received epidermal growth factor receptor
(EGFR)-targeted therapy. EGFR andMET GCNs were studied using
fluorescence in situ hybridization (FISH) and were estimated ac-
cording to the University of Colorado Cancer Center (UCCC)
criteria. For MET, we also assessed GCNs using the Cappuzzo
system.
Results: FISH-positive MET was observed in 16.7% using the
UCCC criteria; specifically, amplification was seen in 3.9% and high
polysomy in 12.8%. FISH-positive MET status was significantly
correlated with FISH-positive EGFR (p  0.003). In the Cappuzzo
system, high MET GCN (mean, 5 copies/cell) was found in 6.7%
and also associated with FISH-positive EGFR (p  0.031). MET
gene copy status was not associated with gender, smoking history,
histology, or stage. However, true MET amplification was more
frequent in patients with SCC than in those with adenocarcinoma.
FISH-positive MET status predicted worse survival in patients with
NSCLC at advanced stages (p  0.034) and in patients with SCC
(p  0.028). In multivariate analyses, increased MET GCN was
significantly associated with shorter survival in patients with SCC,
as analyzed using both the UCCC and Cappuzzo criteria (p  0.019
and 0.008).
Conclusions: Our results suggest that increased MET GCN would
be an independent poor prognostic factor in SCC of the lung.
Key Words: EGFR, FISH, Gene copy number, Gene amplification,
MET, Nonsmall cell lung cancer.
(J Thorac Oncol. 2010;5: 305–313)
MET is a protooncogene that encodes a receptor tyrosinekinase for hepatocyte growth factor/scatter factor. It is
located on chromosome 7q21-31 and is expressed in various
human cancers.1–9 MET is known to be overexpressed in
neoplastic tissues relative to normal surrounding tissues, and
its overexpression is associated with disease progression
through cell proliferation, reduced apoptosis, angiogenesis,
altered cytoskeletal function, and metastasis in some tumors
including nonsmall cell lung cancer (NSCLC).1,3,10 In lung
cancer, c-MET protein was reported to be expressed in 70%
of adenocarcinomas (ADCs), 40% of squamous cell carcino-
mas (SCCs), and up to 100% of NSCLCs at variable levels
and to be associated with a higher tumor stage and a poor
clinical outcome.11–13 Overexpression of circulating c-MET
messenger RNA was correlated with nodal stage and early
recurrence of NSCLC.14
In recent years, the clinical success of epidermal growth
factor receptor tyrosine kinase domain inhibitor (EGFR-TKI)
therapy in NSCLC has encouraged tailored anticancer therapy
against receptor tyrosine kinase, and MET has been considered
a target for anticancer therapy.1,3,15–18 In addition, MET gene
amplification has been shown to be another major mechanism of
acquired resistance to EGFR-TKI, apart from secondary muta-
tions in the EGFR gene (e.g., the T790M mutation in exon
20).19,20 Bean et al.21 found MET amplification in 21% of
patients with acquired resistance to gefitinib or erlotinib, but in
only 3% of patients not treated with EGFR-TKI who had
NSCLC.
MET gene amplification has been analyzed in NSCLC
using various assays, including real-time polymerase chain
reaction (RT-PCR), comparative genomic hybridization, and
fluorescence in situ hybridization (FISH). However, the fre-
quency ofMET amplification has been reported to range from
3 to 21% in EGFR-TKI-untreated NSCLC, and its clinico-
pathologic features are complicated according to the detec-
tion method.21–26
FISH has several advantages over other methods in
evaluating gene copy number (GCN) in that it can be
applied to formalin-fixed paraffin-embedded (FFPE) tumor
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tissues archived for routine pathologic diagnosis, thus
allowing one to assess the tumor cells exclusively. Thus,
FISH is now widely used in clinical practice for the
detection of gene amplification to determine therapeutic
strategies, such as, for example, HER2 FISH in breast
cancer. Moreover, increased EGFR GCN (encompassing
high polysomy and amplification) evaluated by FISH was
a strong indicator of EGFR-TKI sensitivity and a predictor
of survival benefit in NSCLC.27
Recently, Cappuzzo et al.24 reported that high MET
GCN (defined as a mean of 5 copies/cell) was observed in
11.1% of NSCLCs and negatively affected patient survival.
However, currently, only a few studies on MET GCN in
NSCLC using FISH are available, and furthermore, no con-
sensus criteria exist to assess the MET copy status in NSCLC
for predicting the prognosis or sensitivity to drugs (including
EGFR-TKI and MET inhibitors).21,24–26 In addition, the clin-
ical implications of MET GCN according to the histology of
NSCLC remain unclear.
Thus, this study aimed to evaluate the MET gene copy
status in NSCLC by FISH using two kinds of interpretation
criteria, namely, the University of Colorado Cancer Center
(UCCC) and Cappuzzo scoring systems. We also sought to
comparatively analyze its clinicopathologic features and
prognostic significance in NSCLC, especially according to
the histology, which might also help in working out a thera-
peutic strategy targeting MET or EGFR.
MATERIALS AND METHODS
Patients
One hundred and eighty Korean patients with NSCLC
who underwent pulmonary resection of a primary tumor at
Seoul National University Hospital between January 1995
and January 2000 with available FFPE tissue were enrolled.
None received EGFR-targeted therapy during the follow-up
period.28 Representative 2-mm diameter cores were taken
from FFPE tissue blocks for constructing a tissue microarray.
The Institutional Review Board of the Seoul National Uni-
versity Hospital approved this study.
FISH Analyses
The FISH assay was performed as described previously.28
Briefly, 4-m thick serial sections from each tissue microar-
ray block were submitted to a dual-color FISH assay using a
MET/CEP7 probe cocktail (Kreatech Diagnotics, Amster-
dam, The Netherlands). After deparaffinization and dehydra-
tion, slides were immersed in 0.2 N HCl, boiled in a micro-
wave in citrate buffer (pH 6.0), incubated in 1 M NaSCN for
35 minutes at 80°C, immersed in pepsin solution, and then
fixed in 10% neutral-buffered formalin. The DNA probe set
was applied onto the slides, and then incubated in a humid-
ified chamber at 73°C for 5 minutes to codenature the target
DNA and probe, and subsequently at 37°C for 19 hours to
achieve hybridization. After the posthybridization washing,
the slides were counterstained with 4,6-diamidino-2-phe-
nylindole (DAPI) and antifade compound (p-phenylenedi-
amine). FISH signals for each locus-specific FISH probe
were assessed using an Olympus BX51TRF microscope
(Olympus, Tokyo, Japan) equipped with a triple-pass filter
(DAPI/green/orange; Vysis, Downers Grove, IL). Copy num-
ber per cell was counted in 100 nonoverlapping tumor cell
nuclei. By using the UCCC criteria for EGFR,29 MET gene
status was classified into two groups according to the fre-
quency of tumor cells with specific copy numbers of theMET
gene and the chromosome 7 centromere: FISH-positive MET
encompassed gene amplification (MET to CEP7 ratio 2;
15 copies of theMET signals in10% of tumor cells; small
gene cluster [4–10 copies]; or innumerable tight gene clusters
in 10% the tumor cells) and high polysomy (40% of cells
displaying 4 copies of the MET signal). Alternatively, by
using the Cappuzzo scoring system, cases were classified
into those with a mean of more than or equal to 5 copies
per cell (high MET GCN) and with a mean of less than 5
copies per cell.24
Statistical Analysis
The SPSS software (version 12.0 K for Microsoft
Windows®; SPSS Inc., Chicago, IL) was used for statistical
analyses. The relationships between and among groups were
compared using Pearson’s 2 test for qualitative variables and
Student t test for continuous variables. Overall survival (OS)
was determined from the date of surgery to death by disease
or the last follow-up date, and progression-free survival
(PFS) was calculated from the date of surgery to the first
relapse or metastasis, or the last follow-up date. The 95%
confidence intervals (CIs) were evaluated and plotted by
survival analysis with the Kaplan-Meier method using the
log-rank test for comparisons between groups. Multivariate
analysis was performed using Cox proportional hazards re-
gression analysis with a stepdown procedure. All statistical
tests were two-sided, and statistical significance was defined
as p  0.05.
RESULTS
Patient Characteristics
The clinical characteristics of all 180 patients are sum-
marized in Table 1. The patients were primarily men (77.8%)
and in early pathologic stages (69.4%; stage I–II). The me-
dian age was 60 years (range, 28–81 years). Most of the
patients were diagnosed with either SCC (53.9%) or ADC
(40%). Patients with ADC were younger than those with SCC
(p 0.006). Former or current smokers represented 53.3% of
all patients and were more common in SCC than in ADC
(p  0.001). The median OS was 56 months (range, 1–121
months), and the median PFS was 17 months (range, 1–111
months). Mean OS and mean PFS were much longer in stage
I to II than in stage III to IV (mean SD, 59.8 30.7 months
versus 35.3  31.2 months; p  0.001 and 40.3  34.6
versus 18  22.4 months; p  0.001, respectively).
MET FISH
TheMET GCN was measured using FISH and analyzed
according to both the UCCC and Cappuzzo scoring systems
(Figure 1). When UCCC criteria were applied, 30 (16.7%)
cases in total were considered MET FISH-positive. Specifi-
cally, 23 (12.8%) patients showed high polysomy, and 7
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(3.9%) showed gene amplification. High polysomy patients
included 10 SCCs, 11 ADCs, 1 large cell carcinoma, and 1
carcinosarcoma. MET FISH status was not associated with
gender, smoking history, histologic types, lymph node
status, or pathologic stage (Table 2). By using the Cap-
puzzo scoring system for MET GCN, high MET GCN
(mean, 5 copies per cell) was observed in 12 (6.7%)
cases, consisting 5 high polysomy and 7 gene amplification
cases based on UCCC criteria. No significant differences
were observed in gender, smoking status, histology, lymph
node status, or pathologic stage between patients with and
without high MET GCN (Table 2). In contrast, of the seven
patients with true MET gene amplification, six were men
and one was woman. Six (6.2%) of 97 patients with SCC
showed MET amplification; however, no patients with
ADC showed MET amplification. These differences in the
incidence of MET amplification between SCC and ADC
were significant (p  0.039).
In a previous report using the same study cohort, we
showed that EGFR FISH positivity was more common in
nonsmokers and was associated with a tendency for a poor
prognosis.28 To evaluate the prognostic implication of
MET GCN in the context of EGFR FISH status, we
compared the MET gene copy status with EGFR FISH
results (the latter had been analyzed using UCCC criteria).
EGFR FISH-positive status was significantly associated
with MET FISH positive (p  0.003) and high MET GCN
(p  0.031; Table 2). However, true gene amplifications of
MET and EGFR occurred and were mutually exclusive
(Table 2).
Survival Analyses
We first analyzed patient survival according to MET
FISH status based on the UCCC criteria. On the whole,
patients with MET FISH-positive NSCLCs showed a ten-
dency for poorer prognoses than those who were MET FISH-
negative, although the difference was not significant (median
OS, 69 versus 87 months; p  0.416; Figure 2A). MET
FISH-positivity was significantly associated with a shorter
OS in SCC (median OS, 49 versus 81 months; p  0.028;
Figure 2E). In stage III to IV NSCLCs, OS was significantly
worse in the MET FISH-positive group (median OS, 23
FIGURE 1. FISH images from MET FISH
NSCLCs. A, A case with MET high polysomy
showed more than 4 copies of the MET gene
(orange signal) in more than 40% of tumor
cells. B, An example of MET amplification re-
vealed small (4–10 copies) or innumerable
tight MET gene clusters or more than 15 cop-
ies of the MET gene in more than 10% of tu-
mor cells. The MET to CEP7 (green signal) ratio
exceeded 2. NSCLC, nonsmall cell lung cancer;
FISH, fluorescence in situ hybridization.
TABLE 1. Clinicopathologic Characteristics of NSCLC Patients According to
Histologic Types
SCC (n  97) ADC (n  72) Othersa (n  11) p
Age (yr)
Median 62 59 63 0.006b
Mean  SD 61.93  7.62 58.22  9.74 62.45  5.41
Sex, n (%)
Male 90 (92.8) 40 (55.6) 10 (90.9) 0.000
Female 7 (7.2) 32 (44.4) 1 (9.1)
Smoking status, n (%)
Never 27 (29) 46 (65.7) 4 (40) 0.000
Ever 66 (71) 24 (34.3) 6 (60)
Smoking amount
Median (pack yr) 40 0 37.5 0.000b
Mean  SD (pack yr) 33.39  26.82 13.04  20.55 25.50  22.42
Pathologic stage, n (%)
I 44 (45.4) 33 (45.8) 8 (80) 0.016
II 28 (28.9) 12 (16.7) 0
III 25 (25.8) 24 (33.3) 1 (10)
IV 0 3 (4.2) 1 (10)
a Others include large cell carcinoma (n  8) and sarcomatoid carcinoma (n  3).
b Mean age and mean smoking are compared by Student t test between squamous cell carcinoma and adenocarcinoma
patients.
SCC, squamous cell carcinoma; ADC, adenocarcinoma.
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versus 13 months; p  0.034; Figure 2D). However, no
difference in OS was found between the MET FISH-positive
and -negative groups among patients with ADC or stage I to
II NSCLC. PFS also tended to be shorter in those who were
MET FISH positive, regardless of stage or histology, but this
was also not significant (data not shown).
As illustrated in Figure 2B, F, patients having NSCLC
withMET gene amplification had shorter OS than those without
MET amplification; the difference was significant in SCC (p 
0.013). Among the MET FISH-positive NSCLCs, patients with
gene amplification showed worse OS than those with high
polysomy, but the difference was not significant (Figure 2C).
The Cappuzzo scoring system for MET GCN was much
like the UCCC criteria in terms of predicting the prognosis. As
summarized in Table 3, patients with high MET GCN (5 per
cell) tended to have shorter OS and PFS than those with low
MET GCN (5 per cell). The difference was also significant
only in SCC (median OS, 80 versus 13 months; p  0.013).
When analyzed in the context of EGFR FISH status,
high MET GCN (5 per cell) was associated with signifi-
cantly shorter OS than low MET GCN among EGFR FISH-
negative NSCLCs (p  0.009; Figure 3A; Table 3). Other-
wise, no survival difference was detected according to MET
FISH status in the EGFR FISH-negative or -positive groups
(Figure. 3B–D).
Prognostic Implications of MET
Finally, to determine the importance of MET GCN as
an independent prognostic value, univariate and multivariate
survival analyses were performed using the Cox proportional
hazard model, including age, gender, smoking history, patho-
logic stage, MET GCN, and EGFR FISH status. In a univar-
iate analysis of patients with SCC, increased MET GCN,
defined by the Cappuzzo system or the UCCC criteria, was
significantly associated with a higher risk of death (hazard
ratio [HR]  2.865, 95% CI  1.197–6.857; p  0.018 and
HR  2.124, 95% CI  1.065–4.234; p  0.032, respec-
tively; Table 4). On multivariate analysis of patients with
SCC, increasedMET GCN according to the Cappuzzo system
or the UCCC criteria was confirmed to be an independent
poor prognostic indicator (HR  3.365, 95% CI  1.380–
8.203; p  0.008 and HR  2.330, 95% CI  1.151–4.713;
p  0.019, respectively; Table 4). Patients having SCC with
MET amplification also showed shorter OS than those with-
out MET amplification in a multivariate analysis (HR 
3.192, 95% CI  1.232–8.275; p  0.017).
TABLE 2. Clinicopathologic Features of NSCLC Patients According to the MET Gene Copy Status Based on the UCCC Criteria
and Cappuzzo Scoring Systems
UCCC Criteriaa
pc pd
Cappuzzo Systemb
p
value
MET FISH
(n  150)
MET FISH (n  30)
MET < 5
(n  168)
MET > 5
(n  12)
HP
(n  23)
Amp
(n  7)
Sex, n (%)
Male (n  140) 118 (84.3) 16 (11.4) 6 (4.3) 0.521 1.000 131 (93.6) 9 (6.4) 0.811
Female (n  40) 32 (80.0) 7 (17.5) 1 (2.5) 37 (92.5) 3 (7.5)
Smoking, n (%)
Never (n  77) 66 (85.7) 9 (11.7) 2 (2.6) 0.544 0.464 73 (94.8) 4 (5.3) 0.419
Ever (n  96) 79 (82.3) 12 (12.5) 5 (5.2) 88 (91.7) 8 (8.3)
Histology, n (%)
SCC (n  97) 81 (83.5) 10 (10.3) 6 (6.2) 0.831e 0.039e 89 (91.8) 8 (8.2) 0.288e
ADC (n  72) 61 (84.7) 11 (15.3) 0 69 (95.8) 3 (4.2)
Others (n  11) 8 (72.7) 2 (18.2) 1 (9.1) 10 (90.9) 1 (9.1)
Lymph node, n (%)
Negative (n  100) 81 (81) 14 (14) 5 (5) 0.367 0.467 94 (94) 6 (6) 0.672
Positive (n  79) 68 (86.1) 9 (11.4) 2 (2.5) 73 (92.4) 6 (7.6)
Stage, n (%)
I, II (n  125) 104 (83.2) 16 (12.8) 5 (4) 0.741 1.000 117 (93.6) 8 (6.4) 0.805
III, IV (n  54) 46 (85.2) 6 (11.1) 2 (3.7) 50 (92.6) 4 (7.4)
EGFR FISH, n (%)
Negative (n  125) 111 (88.8) 10 (8) 4 (3.2) 0.003 0.438 120 (96) 5 (4) 0.031
Positive (n  55) 39 (70.9) 13 (23.6) 3 (5.5) 48 (87.3) 7 (12.7)
HP (n  36) 22 (61.1) 11 (30.6) 3 (8.3) 30 (83.3) 6 (16.7)
Amp (n  19) 17 (89.5) 2 (10.5) 0 18 (94.7) 1 (5.3)
a The University of Colorado Cancer Center (UCCC) criteria.
b MET FISH-positive group was defined mean MET gene copy number 5 copies per cell.
c MET FISH vs MET FISH.
d MET Amp vs Amp.
e SCC vs ADC.
HP, high polysomy; Amp, amplification; SCC, squamous cell carcinoma; ADC, adenocarcinoma; FISH, fluorescence in situ hybridization.
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DISCUSSION
Our study revealed that high MET GCN was observed
in 6.7% of the cases, as estimated by the Cappuzzo system,
and the MET FISH-positive rate was 16.7%, according to
UCCC criteria (3.9% of gene amplification and 12.8% of high
polysomy). In several studies, the frequency of MET ampli-
fication has been variably reported to be from 3 to 21% in
patients having NSCLC who were not treated with EGFR-
FIGURE 2. Kaplan-Meier curves
using the log-rank test showing the
overall survival of all NSCLC patients
(A, B), NSCLC patients with MET
FISH (C), NSCLC patients with
stage III–IV (D), and SCC patients
(E, F) according to the MET FISH
and FISH, or MET gene amplifica-
tion status based on the UCCC cri-
teria. NSCLC, nonsmall cell lung
cancer; FISH, fluorescence in situ
hybridization; SCC, squamous cell
carcinoma; UCCC, the University of
Colorado Cancer Center.
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TKI.21–26 In these studies, different detection methods (e.g.,
RT-PCR, comparative genomic hybridization, and FISH) and
different interpretation criteria were used, which may account
for the wide range of rates detected. To address these prob-
lems, we analyzed MET gene amplification in NSCLC using
FISH and 2 modified criteria. Recent studies using quantita-
tive RT-PCR demonstrated different rates of MET amplifica-
tion, with 5.6 versus 21% in NSCLC,22,23 indicating that
RT-PCR is not a reliable method for evaluating molecular
modification of the MET gene. Moreover, FISH is generally
accepted to be better than RT-PCR for evaluating GCN,
because it enables us to exclusively estimate the tumor cells,
with little contamination of nonneoplastic cells. Nevertheless,
the interpretation criteria of MET GCN using FISH in
NSCLC have not been well established. In a few previous
studies, MET amplification or FISH-positive status were
determined according to a cutoff value, which was modified
from the criteria for HER2 FISH in breast cancer or EGFR
FISH in NSCLC.24,25 In a recent study, Cappuzzo et al.24
defined high MET GCN as a mean of more than or equal to
5 copies per cell for the evaluation of MET amplification in
NSCLC. Thus, to comparatively evaluate the MET GCN, we
determined MET amplification in NSCLC according to both
the UCCC criteria for EGFR FISH in NSCLC and the
Cappuzzo scoring system.24,29
EGFR FISH-positive status is more common in non-
smokers and is considered to be a marker for poor prognosis
in EGFR-TKI-untreated NSCLC, whereas it is an indicator of
survival benefit in patients with EGFR-TKI-sensitive
NSCLC.27,28 The rates of increased EGFR GCN (so-called
EGFR FISH-positive by the UCCC criteria) are similar be-
tween Korean and Western patients with NSCLC. However,
gene copy status of MET between East Asian and Western
patients with NSCLC has not been analyzed or compared. In
this study, all patients were Koreans (i.e., East Asians),
whose NSCLCs are characterized by a much higher incidence
of EGFR gene mutations than in Western populations.30
Moreover, Cappuzzo et al.24 demonstrated that MET ampli-
fication was detected in 11.1% of patients with primary
NSCLC (from Italy), which was an independent poor prog-
nostic factor. The results of our study and Cappuzzo et al.’s
suggest that little ethnic difference in MET gene copy status,
especially for amplification, may exist in NSCLC.
The clinicopathologic features of MET amplification in
NSCLC are conflicting in several studies. Okuda et al.23
reported that increased MET GCN was observed in 5.6% of
patients with NSCLC, who were men and smokers, whereas
no difference in MET GCN status was seen in terms of
histologic types. In contrast, another group reported thatMET
amplification (or high GCN) was not significantly associated
with gender, smoking history, or histology.21,24 Consistent
with this study, we also found no significant correlation
between increasedMET GCN (either by the UCCC criteria or
Cappuzzo system) and gender, smoking history, or histology.
However, most patients with true MET amplification were
men and ever smokers, and had SCC (Table 2), suggesting
that MET amplification may be more involved in the onco-
genesis of SCC than ADC. Furthermore, patients having SCC
with true MET amplification showed markedly shorter OS
than those without MET amplification (Figure 2F). MET
FISH-positive status (by UCCC criteria) or high MET GCN
(5 copies per cell) predicted significantly shorter OS in
patients with SCC in both univariate and multivariate analy-
ses (Figure 2; Tables 3 and 4). The recent study by Cappuzzo
et al.24 using FISH was consistent with our results, demon-
strating that high MET GCN was an independent negative
TABLE 3. Overall Survival and Progression-Free Survival of NSCLC Patients According
to MET Gene Copy Number Based on the Cappuzzo Scoring System
Overall Survival Progression-Free Survival
MET <5
(n/moa)
MET >5
(n/moa) p
MET <5
(n/moa)
MET >5
(n/moa) p
Sex
Male 131/87 9/42 0.179 131/38 9/14 0.416
Female 37/70 3/69 0.531 37/16 3/9 0.408
Smoking
Never 73/55 4/13 0.324 73/16 4/9 0.348
Ever 88/82 8/42 0.158 88/96 8/14 0.272
Histology
SCC 89/80 8/13 0.013 89/63 8/7 0.063
ADC 69/87 3/69 0.880 69/19 3/24 0.804
Stage
I, II 117/84 8/69 0.524 117/81 8/14 0.562
III, IV 50/20 4/11 0.101 50/10 4/5 0.368
EGFR FISH
Negative 120/78 5/13 0.009 120/38 5/5 0.051
Positive 48/49 7/69 0.778 48/19 7/24 0.841
a Median survival.
SCC, squamous cell carcinoma; ADC, adenocarcinoma; FISH, fluorescence in situ hybridization.
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FIGURE 3. Kaplan-Meier curves
using the log-rank test showing the
overall survival of MET FISH and
FISH, or gene copy number status
according to EGFR FISH NSCLCs,
(A, B) and EGFR FISH NSCLCs (C,
D). FISH, fluorescence in situ hybrid-
ization; NSCLC, nonsmall cell lung
cancer; EGFR, epidermal growth fac-
tor receptor.
TABLE 4. Univariate and Multivariate Overall Survival Analyses in Patients with Squamous Cell Carcinoma
Variable (Category)
Univariate
p
Multivariate
pa pbHR 95% CI HR 95% CI
Age NT NT 0.230 1.043 1.002–1.085 0.041 —
NT NT — 0.148
Sex (female/male) NT NT 0.905 NT NT 0.854 0.722
Smoking (never/ever) NT NT 0.095 NT NT 0.059 0.170
Stage (III, IV/I, II) 2.542 1.350–4.785 0.004 2.824 1.435–5.559 0.003 —
2.487 1.288–4.803 — 0.007
MET GCNa (5/5 copies) 2.865 1.197–6.857 0.018 3.365 1.380–8.203 0.008 —
MET FISHb () 2.124 1.065–4.234 0.032 2.330 1.151–4.713 — 0.019
EGFR FISHb () NT NT 0.056 NT NT 0.215 0.131
MET amplification also showed shorter OS than those without MET amplification in multivariate analysis (HR  3.192, 95% CI  1.232–8.275; p  0.017).
a Cappuzzo system.
b UCCC criteria.
NT, not tested; HR, hazard ratio; CI, confidence interval; GCN, gene copy number.
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prognostic factor in surgically resected NSCLC, although
their analysis did not address histologic types of NSCLC.
Moreover, other groups have reported that in SCC of the head
and neck and uterine cervix, c-MET overexpression was an
important indicator of a poor prognosis.31,32 These findings
suggest that increased MET GCN might reflect an aggressive
biologic behavior in SCC or NSCLC. Unlike SCC of the
lung, no significant difference in prognosis was found in
patients having ADC with MET FISH-positive and -negative
status in our study. In contrast to our results, Beau-Faller et
al.22 found a tendency toward shorter event-free survival in
patients with increased MET GCN, only in ADC. However,
these results were not significant. Furthermore, the prognostic
implication of overexpression of the c-MET protein in ADC
of the lung is also controversial.11 Combined, these findings
suggest that increased MET GCN is an independent poor
prognostic indicator in SCC, rather than ADC, of the lung. In
addition, we suggest that de novo increase of MET GCN in
NSCLC might have a different influence on the clinical
outcome, depending on the histologic subtype.
Although the incidence ofMET amplification in EGFR-
TKI-untreated NSCLC is only about 4%, MET amplification
was found in up to 21% of patients with NSCLC after
prolonged exposure to the EGFR-TKIs (gefitinib and erlo-
tinib), which eventually leads to acquired resistance to the
drugs by activating ERBB3 signaling.19,21,33–35 Moreover,
EGFR mutation or MET amplification activated MET onco-
protein in NSCLC untreated with EGFR-TKIs.36 Based on
these findings, we suggest that increased MET amplification
in NSCLC might have biologic relevance to EGFR-mediated
signals in tumor cells, resulting in modification of biologic
behavior in NSCLC. To address this issue, we analyzed the
MET FISH status in the context of EGFR GCN in NSCLC.
Increased MET GCN based on the UCCC criteria or the
Cappuzzo system was significantly correlated with EGFR
FISH-positive status, and the association strength was higher
when analyzing MET status using the UCCC criteria. How-
ever, MET amplification and EGFR amplification occurred in
a mutually exclusive manner in our study cohort. These
results were consistent with the previous study by Cappuzzo
et al.,24 which demonstrated that MET FISH status was
significantly associated with EGFR FISH status and that
coamplification of MET and EGFR genes (only 1.1% in their
cohort) were rare. Consequently, they also suggested that the
association of MET and EGFR FISH may be partly because
of chromosome 7 polysomy. However, the exclusive occur-
rence of MET and EGFR amplification leads us to suggest
that genetic alterations other than chromosome 7 polysomy
might contribute to the pathogenesis of NSCLC through the
MET or EGFR pathways. Moreover, our study revealed that
high MET GCN (5 copies per cell) predicted significantly
poor prognosis in NSCLCs with EGFR FISH-negative status,
whereas MET GCN had no survival influence on the EGFR
FISH-positive NSCLCs, consistent with Cappuzzo et al.’s
observation.24 Thus, the prognostic implications of increased
MET GCN may be different depending on the EGFR gene
status.
MET not only being a target to overcome the resistance
to EGFR-TKI but also has been considered as a potential
therapeutic target for anticancer treatment, which has led to
the development of several kinds of MET inhibitors, some of
which exhibit good efficacy in treating NSCLC.1,3,13,17,18
Increased MET GCN in NSCLC is useful as an independent
poor prognostic marker and may also be a therapeutic target
to improve clinical outcome in patients by inhibiting MET.
Moreover, MET FISH status may be helpful in identifying a
group of NSCLCs eligible for MET-targeted therapy. For
analyzing MET GCN in our study, the Cappuzzo system
seems to be more appropriate than the UCCC criteria in terms
of predicting the prognosis of EGFR-TKI-untreated
NSCLCs. However, which system would be more effective to
sensitively predict MET-targeted therapy remains to be de-
termined.
In conclusion, our results suggest that increased MET
GCN would be an independent poor prognostic factor in
primary SCC of the lung.
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